Drug Interactions between HIV Protease Inhibitors and Acid-Reducing Agents

• Published in: Clinical pharmacokinetics Vol. 47; no. 2; pp. 75 - 89
• Main Authors: Falcon, Ronald W., Kakuda, Thomas N.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.01.2008; Adis international; Wolters Kluwer Health, Inc
• Subjects: Antacids - adverse effects; Antacids - pharmacokinetics; Antacids - therapeutic use; Antiretroviral Therapy, Highly Active - adverse effects; Biological and medical sciences; Biological Availability; Drug Interactions; General pharmacology; HIV Infections - blood; HIV Infections - drug therapy; HIV Protease Inhibitors - adverse effects; HIV Protease Inhibitors - pharmacokinetics; HIV Protease Inhibitors - therapeutic use; Humans; Internal Medicine; Medical sciences; Medicine; Medicine & Public Health; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Review Article; Omeprazole; Saquinavir; Ritonavir; Esomeprazole; Indinavir; Human; Antiretroviral agent; Retroviridae; Review; Lentivirus; Antihistaminic; Proton pump inhibitor; Virus; Antiviral; Drug interaction; Human immunodeficiency virus; Antiacid; Protease inhibitor; H2 Histamine receptor

Maximal efficacy of protease inhibitor-based antiretroviral therapy for HIV/AIDS requires adequate drug absorption and bioavailability. However, the use of acid-reducing agents in patients treated with highly active antiretroviral therapy is common and may induce clinically significant drug-drug int...